Get started
Author

Francesco Maura

Observed names: F Maura, F. Maura, Francesco Maura,, MAURA, FRANCESCO, Maura F, Maura, Francesco
Observed institutions: University of Messina, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Memorial Sloan Kettering Cancer Center, Harvard University, University of Padua, University of Miami, German Cancer Research Center, University of Milan, University of Ferrara, Cornell University, Wellcome Sanger Institute, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Magna Graecia University, University of Catania, Santa Maria Nuova Hospital, Ferrarotto Hospital, Dana-Farber Cancer Institute, Ospedale Policlinico San Martino, Azienda Ospedaliera Pugliese Ciaccio, Ospedale San Bortolo, Fondazione IRCCS Istituto Nazionale dei Tumori, Sylvester Comprehensive Cancer Center, Weill Cornell Medicine, Centro de Investigación Médica Aplicada, Fondazione 'Alberto e Antonietta Matarelli', Bocconi University, Universidad de Navarra
ORCID: 0000-0002-5017-1620
Observed ORCIDs: 0000-0002-5017-1620, 0000-0001-6233-4864
OpenAlex ID: A5091566972
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
2018 · Thomas J. Mitchell, Samra Turajlic, et al. · Cell · 513
PDF
The mutational landscape of normal human endometrial epithelium
2020 · Luiza Moore, Daniel Leongamornlert, et al. · Nature · 499
PDF
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition
2020 · Bernardo Rodriguez-Martin, Eva G. Alvarez, et al. · Nature Genetics · 449
PDF
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
2023 · Holly Lee, Sungwoo Ahn, et al. · Nature Medicine · 356
PDF
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
2019 · Francesco Maura, Niccoló Bolli, et al. · Nature Communications · 275
PDF
Genomic patterns of progression in smoldering multiple myeloma
2018 · Niccolò Bolli, Francesco Maura, et al. · Nature Communications · 222
PDF
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
2018 · Niccolo Bolli, Giulia Biancon, et al. · Leukemia · 196
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
2025 · Hervé Avet-Loiseau, Faith E. Davies, et al. · Journal of Clinical Oncology · 192
A practical guide for mutational signature analysis in hematological malignancies
2019 · Francesco Maura, Andrea Degasperi, et al. · Nature Communications · 183
PDF
Timing the Initiation of Multiple Myeloma
2019 · Even H. Rustad, Venkata Yellapantula, et al. · Nature Communications · 164
PDF
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
2022 · Ferran Nadeu, Romina Royo, et al. · Nature Medicine · 138
PDF
Genomic Classification and Individualized Prognosis in Multiple Myeloma
2024 · Francesco Maura, Arjun Raj Rajanna, et al. · Journal of Clinical Oncology · 129
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
2021 · Bénedith Oben, Guy Froyen, et al. · Nature Communications · 129
PDF
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
2021 · Eileen M. Boyle, Shayu Deshpande, et al. · Nature Communications · 128
PDF
Revealing the Impact of Structural Variants in Multiple Myeloma
2020 · Even H. Rustad, Venkata D. Yellapantula, et al. · Blood Cancer Discovery · 123
Autoimmune cytopenias in chronic lymphocytic leukemia
2014 · Carlo Visco, Wilma Barcellini, et al. · American Journal of Hematology · 123
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
2021 · Ola Landgren, Malin Hultcrantz, et al. · JAMA Oncology · 119
PDF
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
2017 · F Maura, M Petljak, et al. · Leukemia · 117
PDF
Diverse mutational landscapes in human lymphocytes
2022 · Heather E. Machado, Emily Mitchell, et al. · Nature · 116
PDF
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
2021 · Benjamin Diamond, Neha Korde, et al. · The Lancet Haematology · 96
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma
2022 · Michael D. Jain, Bachisio Ziccheddu, et al. · Blood · 90
PDF
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
2024 · Holly Lee, Michael Durante, et al. · Blood · 84
PDF
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
2020 · Malin Hultcrantz, Joshua Richter, et al. · Blood Cancer Discovery · 82
PDF
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
2022 · Leo Rasche, Carolina Schinke, et al. · Nature Communications · 78
PDF
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
2020 · Bachisio Ziccheddu, Giulia Biancon, et al. · Blood Advances · 78
Works count: 806
Citation count: 7,281
H-index: 41
I10-index: 102
Year
Topic
Type